In this study, the majority of patients was under continuous subcutaneous insulin infusion (CSII) therapy and performed self-monitoring of blood glucose (SMBG) 4–6 times per day, which is currently an important tool for diabetes care that helps patients, caregivers and the diabetes team to adjust insulin therapy during hypoglycemia, hyperglycemia, physical activity, stress, illness and carbohydrate counting [8]. The gene discussed is INS; the disease is Hyperglycemia.